CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
Manufacturers running legacy PROMIS or first-gen MES can apply 25% of current maintenance spend toward a modern Eyelit MOM/MES subscription. Legacy PROMIS and first-generation MES platforms now ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
Zacks Investment Research on MSN
All you need to know about Promis Neurosciences (PMN) rating upgrade to buy
Promis Neurosciences (PMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
In a recent transaction, Neil Cashman, the Chief Scientific Officer of ProMIS Neurosciences Inc. (NASDAQ:PMN), acquired 15,000 common shares of the company at $0.973 per share. The purchase comes as ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
ProMIS Neurosciences Inc., a clinical-stage biotechnology firm, announced its plan to present preclinical data on novel computationally-derived vaccines targeting neurodegenerative diseases at the ...
Social determinants of health and utilization of neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC) in the community oncology setting. The proliferation biomarker SPAG5 ...
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results